Close Menu

Alan Crane

Jun 23, 2015

Alan Crane has resigned from the board of T2 Biosystems, effective immediately, in order to pursue other business opportunities, the company said in a document filed with the US Securities and Exchange Commission. Crane served on the firm's compensation committee. 

More Like This

May 15, 2019

Norman Winarsky

Predictive analytics firm Interpreta has hired Norman Winarsky as vice president of artificial intelligence and natural-language analytics. In that capacity, Winarsky will supervise development of voice, image, and natural-language interpretation technologies for the company. Winarsky, a former president of SRI Ventures, cofounded the Siri voice assistant.

May 13, 2019

Jan Groen

Novigenix has appointed Jan Groen as the firm's CEO and member of its board of directors. Prior to Novigenix, Groen served as president and CEO of MDxHealth. Groen is co-founder of ViroClinics, founder and CEO of DxOrange, and currently serves on the board of Angle and Destina Genomics. 

May 10, 2019

Nancy White

Inagene Diagnostics has appointed Nancy White as its CEO. White joined the firm in January as VP of sales and marketing. Prior to Inagene, White held several management roles at Novartis and Novartis Oncology from 2008 to 2018, including VP and franchise head, retina, region LACan; as well as global team lead, advancing commercial excellence, innovative customer models. Before Novartis, White served in multiple roles at Allergan from 2003 to 2008. Prior to Allergan, she held roles at Eli Lilly from 1999 to 2003. 

May 09, 2019

Sun Kim

Centogene has appointed Sun Kim as its chief strategy and investor relations officer. Prior to Centogene, Kim served as head of corporate strategy at Shire Pharmaceuticals. Before Shire, Kim worked at Alcon for six years, where he served in multiple roles including head of strategy and general manager of Alcon Singapore.

May 08, 2019

Christian Meisel

Molecular Health has appointed Christian Meisel as its chief medical officer. Prior to Molecular Health, Meisel worked at Roche, where he served in multiple leadership roles including global head of its personalized healthcare platform, acting global head of translational medicine oncology, and global head of biomarkers and translational R&D innovation. 

May 07, 2019

David Parker, Mike Evans

David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx. 

May 02, 2019

Sue Paish

Contextual Genomics has appointed Sue Paish as the chair of its board of directors. She will be replacing Chris Wagner, who is stepping down but will remain a director. Paish is currently CEO of the Digital Technology Super Cluster, chair of the board of directors of the Business Council of British Columbia, and a director of CORIX Group. Paish joined Contextual Genomics in 2018 and previously served as president and CEO of LifeLabs Medical Laboratory Services. Prior to LifeLabs, Paish served as CEO of Pharmasave and managing partner of Fasken. 

Apr 30, 2019

Brent Satterfield

Co-Diagnostics has announced that Brent Satterfield, one of the firm's directors, has resigned from its board. He will remain as the firm's CSO. 

Apr 30, 2019

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

Apr 30, 2019

Ron McGrath

Inscripta has appointed Ron McGrath as its CFO. McGrath has held various leadership and financial roles in the biotechnology and information technology industries. Prior to Inscripta, McGrath served as VP of finance at Illumina. He also served as chief of staff for the company's operations. Before joining Illumina, McGrath held financial leadership roles at Memec and DJ Orthopedics.

Apr 25, 2019

Alfred Bowie Jr.

Veracyte has named Alfred Bowie Jr. as vice president of corporate and business development where he will lead the company's strategic planning process. Previously, Bowie led strategic planning, corporate development and competitive intelligence at Foundation Medicine, a Roche subsidiary, and served in corporate and business development positions at Tecan Group and Danaher Corporation. He has also worked in management consulting at the Boston Consulting Group.

Apr 25, 2019

Darrin Crisitello, Nigel Beard, Marcel Roche

Mission Bio has appointed three members to its executive team, including Darrin Crisitello as chief commercial officer, Nigel Beard as senior VP of research and development, and Marcel Roche as senior VP of finance and administration. Prior to Mission Bio, Crisitello led global clinical teams at Color Genomics and Natera. Crisitello has over 19 years of experience in commercial leadership and business development in next-generation sequencing, microfluidics, artificial intelligence, and machine learning, Beard has launched more than 50 products and has been an inventor on more than 40 patents. He has previously worked at firms such as GlaxoSmithKline and Life Technologies, as well as startups like Feetz. Prior to Mission Bio, Roche served as VP of finance at Achaogen and at Guardant Health.

Apr 25, 2019

Piet Houwen, Dirk Zimmermann, Hilde Eylenbosch

Biocartis has announced several changes to its management team. The firm has appointed Piet Houwen as its chief operating officer earlier this month. Prior to joining Biocartis, Houwen served as COO at Ablynx. Before Ablynx, he held global roles for Sanofi/Genzyme and Janssen Pharmaceutica (part of Johnson & Johnson family of companies).

Biocartis has also appointed Dirk Zimmermann as its global head pharma collaborations and partnering. Zimmerman will assume the position at the firm in May. Prior to joining Biocartis, Zimmermann held positions at Roche Diagnostics and Qiagen in product development and corporate venturing.

Biocartis has also let go of Hilde Eylenbosch as the firm's chief commercial officer, effective at the end of April. The firm does not have plans to immediately appoint a new CCO, as it will redistribute the tasks to the company's CEO and senior commercial management.

Apr 24, 2019

Andrew Last

Bio-Rad Laboratories has appointed Andrew Last as executive VP and chief operating officer, responsible for all operating functions of the company on a global basis. Last was most recently CCO at Berkeley Lights and prior to that he served as COO at Intrexon. He was executive VP and COO at Affymetrix between 2010 and 2016, and has also previously held senior positions at Becton Dickinson, Applied Biosystems, Incyte Genomics, and Monsanto.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its board of directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive VP of AstraZeneca and was president of MedImmune, a subsidiary of AstraZeneca, after holding various other research and development positions at the firm. Jallal is a member of the board of trustees at Johns Hopkins University and of UMB Health Sciences Research Park. She has also served as a past president of the Association for Women in Science.

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.